Zalgen Revenue and Competitors
Estimated Revenue & Valuation
- Zalgen's estimated annual revenue is currently $1.7M per year.
- Zalgen's estimated revenue per employee is $155,000
Employee Data
- Zalgen has 11 Employees.
- Zalgen grew their employee count by 0% last year.
Zalgen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Zalgen?
Zalgen is a leading biotechnology company whose dedicated team of scientists are providing significant research, diagnostics, and therapeutic solutions for serious viral infectious diseases. The company is dedicated to developing and deploying medical interventions to save the lives of individuals around the world suffering from these often-overlooked diseases. Since 2011, Zalgen has focused its efforts on targeting neglected and underrepresented human viral infectious diseases, particularly viral hemorrhagic diseases that include the Ebola virus (EBOV) and the Lassa virus (LASV). Currently, the company has applied its expertise in serious viral infectious diseases—pivoting this year to address the SARS CoV-2 pandemic by developing antibody tests.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Germantown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 11 | 57% | N/A |
#2 | $1M | 11 | 10% | N/A |
#3 | $1M | 12 | -14% | N/A |
#4 | $1M | 12 | -45% | N/A |
#5 | $1.9M | 12 | N/A | N/A |